Larry V Rubinstein - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Larry V Rubinstein

Showing results (1-10 of 40) with videos related to

Pageof 4

Sort By:

Frontiers in Oncology|October 5, 2020

Phase 0 Radiopharmaceutical-Agent Clinical DevelopmentCharles A Kunos, Larry V Rubinstein, Jacek Capala, et al.

The Oncologist|April 24, 2014

Are we ready for the 10% solution?Helen X Chen, Larry V Rubinstein, Lalitha K Shankar, et al.

Cancer Medicine|July 31, 2023

Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trialsJunki Mizusawa, Hioryuki Sato, Larry V Rubinstein, et al.

Journal of the National Cancer Institute|September 27, 2007

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?Larry V Rubinstein, Janet E Dancey, Edward L Korn, et al.

Statistics in Medicine|April 27, 2010

The statistics of phase 0 trialsLarry V Rubinstein, Seth M Steinberg, Shivaani Kummar, et al.

Journal of the National Cancer Institute|February 10, 2015

Application of molecular profiling in clinical trials for advanced metastatic cancersShivaani Kummar, P Mickey Williams, Chih-Jian Lih, et al.

Lancet (London, England)|August 14, 2022

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsDai Chihara, Ruitao Lin, Christopher R Flowers, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer InstituteDai Chihara, Erich P Huang, Shanda R Finnigan, et al.

Journal for Immunotherapy of Cancer|December 21, 2025

Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancersJibran Ahmed, Geraldine O'Sullivan Coyne, Larry V Rubinstein, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.

Pageof 4

Search research articles

Showing results (1-10 of 40) with videos related to

Sort By:

Pageof 4

Frontiers in Oncology|October 5, 2020

Phase 0 Radiopharmaceutical-Agent Clinical DevelopmentCharles A Kunos, Larry V Rubinstein, Jacek Capala, et al.

The Oncologist|April 24, 2014

Are we ready for the 10% solution?Helen X Chen, Larry V Rubinstein, Lalitha K Shankar, et al.

Cancer Medicine|July 31, 2023

Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trialsJunki Mizusawa, Hioryuki Sato, Larry V Rubinstein, et al.

Journal of the National Cancer Institute|September 27, 2007

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?Larry V Rubinstein, Janet E Dancey, Edward L Korn, et al.

Statistics in Medicine|April 27, 2010

The statistics of phase 0 trialsLarry V Rubinstein, Seth M Steinberg, Shivaani Kummar, et al.

Journal of the National Cancer Institute|February 10, 2015

Application of molecular profiling in clinical trials for advanced metastatic cancersShivaani Kummar, P Mickey Williams, Chih-Jian Lih, et al.

Lancet (London, England)|August 14, 2022

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsDai Chihara, Ruitao Lin, Christopher R Flowers, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer InstituteDai Chihara, Erich P Huang, Shanda R Finnigan, et al.

Journal for Immunotherapy of Cancer|December 21, 2025

Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancersJibran Ahmed, Geraldine O'Sullivan Coyne, Larry V Rubinstein, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.

Pageof 4